Appili Therapeutics is focused on developing innovative drug solutions to address significant unmet needs in the field of infectious diseases. Their pipeline includes a diverse range of products aimed at tackling various infections, including LIKMEZ™ (ATI-1501), a novel oral formulation of metronidazole designed to treat serious anaerobic and protozoal infections. Additionally, they are advancing ATI-1701, a potential first-in-class live-attenuated vaccine targeting tularemia, a recognized biothreat, and ATI-1801, a topical antiparasitic treatment aimed at addressing disfiguring skin infections prevalent in many regions worldwide. This strategic mix of products reflects Appili's commitment to both immediate and long-term solutions in infectious disease management.

The company employs a unique approach to drug development that emphasizes collaboration with industry partners and government agencies, seeking to align objectives and secure non-dilutive funding for their programs. Appili's pipeline is designed to create value through a combination of near-market opportunities and cutting-edge research, with the potential for certain programs, such as ATI-1701 and ATI-1801, to qualify for FDA Priority Review Vouchers upon approval. This innovative strategy not only enhances their development capabilities but also positions them to transform treatment paradigms for various infectious diseases, ultimately benefiting patients and healthcare providers alike.

Canada

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. 

Appili Therapeutics

Company Details